🇺🇸 FDA
Patent

US 9879231

Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites

granted A61KA61K2039/5256A61K39/285

Quick answer

US patent 9879231 (Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/5256, A61K39/285, A61P, A61P31/14